CoChat

Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation

Lingvay, Ildiko, Sumithran, Priya, Cohen, Ricardo V, le Roux, Carel W · 2022 · The Lancet

The DOI matches its Crossref record; 89 of the 91 references it cites were found in a registry or an index.

Abstract

Obesity is now recognised as a disease that is associated with serious morbidity and increased mortality. One of its main metabolic complications is type 2 diabetes, as the two conditions share key pathophysiological mechanisms. Weight loss is known to reverse the underlying metabolic abnormalities of type 2 diabetes and, as such, improve glucose control; loss of 15% or more of bodyweight can have a disease-modifying effect in people with type 2 diabetes, an outcome that is not attainable by any other glucose-lowering intervention. Furthermore, weight loss in this population exerts benefits that extend beyond glycaemic control to improve risk factors for cardiometabolic disease and quality of life. We review the evidence supporting the role of weight loss in the management of type 2 diabetes and propose that many patients with type 2 diabetes would benefit from having a primary weight-centric approach to diabetes treatment. We discuss the logistical challenges to implementing a new weight-centric primary treatment goal in people with type 2 diabetes.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(21)01919-x

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

7 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

1 retracted

Show all 89 references

Research works printed but not linked: 2

  1. 2021, 8. Obesity Management for the Treatment of type 2 diabetes: Standards of Medical Care in Diabetes-2021, Diabetes Care, 44, S100
  2. Lau DCW, Erichsen L, Francisco AMO, et al. Efficacy and safety of once-weekly cagrilintide for weight management: a randomised, placebo and active-controlled, dose-finding, phase 2 trial. Lancet (in press).

Cited by

See all 640

Metadata

Authors
Lingvay, I., Sumithran, P., Cohen, R. V., & le Roux, C. W.
Affiliations
  • The University of Texas Southwestern Medical Center (US)
  • The University of Melbourne (AU)
  • Hospital Alemão Oswaldo Cruz (BR)
Corresponding author
Lingvay, Ildiko
Venue
The Lancet
Publisher
Elsevier BV
Published
2022-01
Volume
399
Issue
10322
Pages
394-405
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3202575491
Cited by
581
References
91
Citations by year
2026: 97 · 2025: 125 · 2024: 136 · 2023: 144 · 2022: 74
FWCI
13.74
Type
journal article
Language
en
Update notices
erratum (2022-01-22)
Open access
closed
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
obesity, type 2 diabetes, weight loss, disease-modifying effects, glycemic control, cardiometabolic risk factors, quality of life, implementation barriers
MeSH terms
Obesity Management, Diabetes Mellitus, Type 2, Goals, Humans, Hypoglycemic Agents, Obesity, Quality of Life, Risk Factors, Weight Loss

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. https://app.cochat.ai/papers/10.1016/s0140-6736(21)01919-x
The paper
Lingvay, I., Sumithran, P., Cohen, R. V., & le Roux, C. W. (2022). Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. The Lancet. https://doi.org/10.1016/s0140-6736(21)01919-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.